Literature DB >> 31394292

Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches.

Maryam Rostamtabar1, Abolfazl Rahmani1, Masoud Baee2, Ahmad Karkhah2, Vijay Kumar Prajapati3, Soheil Ebrahimpour4, Hamid Reza Nouri5.   

Abstract

Serogroup B of Neisseria meningitidis is the main cause of mortality due to meningococcal meningitis. Despite of many investigations, there is still no effective vaccine to prevent this serious infection. Therefore, this study was conducted to design a multi-epitope based vaccine through immunoinformatics approaches. The T CD4+ and TCD8+ cells along with IFN-γ inducing epitopes were selected from TspA, FHbp, NspA, TbpB, PilQ and NspA antigens form serogroup B of Neisseria meningitidis. Furthermore, to induce strong helper T lymphocytes (HTLs) responses, Pan HLA DR-binding epitope (PADRE) was used. In addition, loop 5 and 7 of the PorB as a TLR2 agonist were added to the vaccine construct. Physico-chemical properties, secondary and tertiary structures of the proposed construct were assessed. Finally, homology modeling, refinement and molecular docking were carried out to evaluated the construct tertiary structure and protein-protein interaction, respectively. By fusing the CTL, HTL and IFN-γ predicted epitopes along with suitable adjuvant and linkers, a multi-epitope vaccine was constructed with a TAT sequence of HIV at the N-terminal. Immunoinformatics analyses confirmed a soluble and non-allergic protein with a molecular weight of 62.5 kDa and high antigenicity. Furthermore, the stability of the multi-epitope construct was established and showed strong potential to generate humoral and cell-mediated immune responses. In addition, through molecular docking and dynamic simulation, the microscopic interaction between the vaccine construct and TLR-2 were verified. In summary, immunoinformatics analysis demonstrated that the constructed multi-epitope vaccine had a strong potential of T and B-cell stimulation and it could possibly be used for prophylactic or therapeutic aims to protect against serogroup B of N. meningitidis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunoinformatics; Multi-epitope vaccine; Neisseria meningitidis; Reverse vaccinology

Mesh:

Substances:

Year:  2019        PMID: 31394292     DOI: 10.1016/j.meegid.2019.103992

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  4 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

2.  Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium.

Authors:  Jyotirmayee Dey; Soumya Ranjan Mahapatra; T Kiran Raj; Taranjeet Kaur; Parul Jain; Arushi Tiwari; Shubhransu Patro; Namrata Misra; Mrutyunjay Suar
Journal:  Gut Pathog       Date:  2022-05-27       Impact factor: 5.324

3.  In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach.

Authors:  Nimat Ullah; Farha Anwer; Zaara Ishaq; Abubakar Siddique; Majid Ali Shah; Moazur Rahman; Abdur Rahman; Xinrui Mao; TingTing Jiang; Bok Luel Lee; Taeok Bae; Amjad Ali
Journal:  J Immunol Methods       Date:  2022-03-25       Impact factor: 2.287

Review 4.  Refining the DC-targeting vaccination for preventing emerging infectious diseases.

Authors:  Yadira Pastor; Nour Ghazzaui; Adele Hammoudi; Mireille Centlivre; Sylvain Cardinaud; Yves Levy
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.